Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
M. Horie, M. Ugajin, M. Suzuki, M. Ohata, S. Noguchi, H. Tamiya, H. Yoshihara, Y. Kichikawa, Y. Sakamoto (Setagayaku Kamiyouga, Hamamatsu, Japan). Diagnostic and prognostic utility of procalcitonin (PCT) measurements in patients with hospitalized community-acquired pneumonia (CAP). Eur Respir J 2009; 34: Suppl. 53, 2361

Member's Comments

No comment yet.

Related content which might interest you: Diagnostic and prognostic value of C-reactive protein in community-acquired pneumonia hospitalized patients Source: Eur Respir J 2004; 24: Suppl. 48, 188s Year: 2004 Predictive value of plasma D-dimer in patients with community-acquired pneumonia (CAP) Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity Year: 2010 The assessment of prognostic rules in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2003; 22: Suppl. 45, 149s Year: 2003 Serum procalcitonin (PCT) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP) Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia Year: 2007 C-reactive protein as severity biomarker in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2005; 26: Suppl. 49, 545s Year: 2005 Could procalcitonin (PCT) be a marker of effectiveness of antibiotic treatment (ABT) in pregnant with not severe community-acquired pneumonia (CAP)? Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015 Procalcitonin and D-dimer to predict prognosis and clinical outcomes in severe community-acquired pneumonia (SCAP) patients Source: Annual Congress 2012 - Respiratory infections: a clinical point of view Year: 2012 The discriminatory value of procalcitonin (PCT) and C-reactive protein (CRP) levels in HIV-seropositive patients presenting with community acquired pneumonia (CAP) due to pulmonary tuberculosis (PTB) compared with patients with pneumococcal pneumonia Source: Eur Respir J 2004; 24: Suppl. 48, 241s Year: 2004 The prognostic value of procalcitonin in patients with hypoxemic COVID 19 pneumonia. Source: Virtual Congress 2021 – COVID - 19 biomarkers Year: 2021 Applicability of Fine criteria in patients hospitalized for community-acquired pneumonia (CAP) Source: Eur Respir J 2005; 26: Suppl. 49, 67s Year: 2005 Biomarkers for the prognostic assessment and disease severity evaluation in community-acquired pneumonia (CAP) Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity Year: 2010 Correlation of procalcitonin and CRP in community-acquired pneumonia with CRB-65 score and prognosis – results from the German competence network CAPNETZ Source: Annual Congress 2006 - Inflammation markers in community-acquired pneumonia Year: 2006 Determining the prognostic value of procalcitonin in ICU patients who developed hospital acquired pneumonia and comparing with sencitive CRP Source: Annual Congress 2009 - Impact of biomarkers in the management of community-acquired pneumonia Year: 2009 Prognostic factors of mortality in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2003; 22: Suppl. 45, 239s Year: 2003 Incidence of ventilator associated pneumonia (VAP) and assessment of serial estimation of procalcitonin levels as a prognostic marker in cases of VAP in a tertiary centre in India Source: Annual Congress 2012 - Scores, biomarkers and risk factors in respiratory infections Year: 2012 Association of CRP values with clinico-radiological appearance in adults with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 374s Year: 2006 Value of routine microbial investigation in low-risk patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2002; 20: Suppl. 38, 420s Year: 2002 Procalcitonin (PCT) and C-reactive protein (CRP) as markers of the differential diagnosis of severe community acquired pneumonia (sCAP) Source: Annual Congress 2013 –Respiratory infections: a combination of problems needing early treatment Year: 2013 Inflammatory biomarkers in predicting ICU admission of severe community-acquired pneumonia (CAP) Source: Annual Congress 2011 - Pulmonary infections and sepsis Year: 2011 Admission CRP and D-dimer levels can identify high-risk patients with community-acquired pneumonia Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity Year: 2010